Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy […]
Bank of America upgraded shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from a neutral rating to a buy rating in a research note issued to investors on Tuesday morning, Marketbeat reports. They currently have $85.00 target price on the stock, up from their prior target price of $52.00. Several other brokerages have also recently […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 18,590,000 shares, an increase of 10.9% from the September 30th total of 16,770,000 shares. Based on an average trading volume of 4,170,000 shares, […]
Picton Mahoney Asset Management reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 12.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,727 shares of the company’s stock after selling 6,048 shares during the quarter. […]
Fiduciary Trust Co. lowered its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 49.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 273,916 shares of the company’s stock after selling 268,375 shares during the quarter. Fiduciary Trust Co.’s holdings in Apellis Pharmaceuticals […]